Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Cash from Operations (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 7 years of Cash from Operations data on record, last reported at 264000.0 in Q3 2025.

  • For Q3 2025, Cash from Operations rose 84.62% year-over-year to 264000.0; the TTM value through Sep 2025 reached 1375000.0, up 77.94%, while the annual FY2024 figure was 4333000.0, 79.6% up from the prior year.
  • Cash from Operations reached 264000.0 in Q3 2025 per CYCN's latest filing, up from 503000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 360000.0 in Q4 2024 and bottomed at 14455000.0 in Q1 2021.
  • Average Cash from Operations over 5 years is 5496894.74, with a median of 6214000.0 recorded in 2023.
  • Peak YoY movement for Cash from Operations: tumbled 96.37% in 2022, then surged 123.36% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 8630000.0 in 2021, then grew by 18.39% to 7043000.0 in 2022, then soared by 78.12% to 1541000.0 in 2023, then soared by 123.36% to 360000.0 in 2024, then crashed by 173.33% to 264000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 264000.0 in Q3 2025, 503000.0 in Q2 2025, and 968000.0 in Q1 2025.